ENTA
NASDAQ · Biotechnology
Enanta Pharmaceuticals Inc
$11.95
-0.47 (-3.78%)
Open$12.33
Previous Close$12.42
Day High$12.33
Day Low$11.87
52W High$17.15
52W Low$7.05
Volume—
Avg Volume253.6K
Market Cap361.74M
P/E Ratio—
EPS$-2.41
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+272.8% upside
Current
$11.95
$11.95
Target
$44.55
$44.55
$33.16
$44.55 avg
$53.28
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 85.46M | 93.73M | 75.01M |
| Net Income | -107,128,454 | -105,753,656 | -19,564,680 |
| Profit Margin | -125.4% | -119.1% | -26.1% |
| EBITDA | -105,654,709 | -110,093,203 | -21,379,947 |
| Free Cash Flow | — | — | -13,998,479 |
| Rev Growth | -8.8% | -8.8% | -3.9% |
| Debt/Equity | 2.21 | 2.21 | 0.40 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $265.08 | -0.05% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $406.09 | -1.01% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $151.37 | -0.85% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $516.34 | +0.26% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $801.82 | -0.26% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $246.51 | -2.04% | 40.0 | 32.33B |